Patent application number | Description | Published |
20080200489 | Combination of Organic Compounds - The invention provides a pharmaceutical combination comprising:
| 08-21-2008 |
20090281159 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF LYMPHOMAS - The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I): | 11-12-2009 |
20100069318 | COMBINATION OF AN HDAC INHIBITOR AND AN ANTIMETABOLITE - The invention relates to a combination which comprises:
| 03-18-2010 |
20100069458 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER - The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination. | 03-18-2010 |
20100137398 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF GASTROINTESTINAL CANCERS - The present invention relates to the use of an HDAC inhibitor for the preparation of a medicament for the treatment of gastrointestinal cancers; a method of treating a warm-blooded animal, especially a human, having gastrointestinal cancer, comprising administering to said animal a therapeutically effective amount of an HDAC inhibitor, especially a compound of formula (I) as defined herein; and to a pharmaceutical composition and a commercial package. | 06-03-2010 |
20100179208 | Use of HDAC Inhibitors for the Treatment of Bone Destruction - The present invention relates to the use of HDAC inhibitors for the treatment of bone destruction caused by cancer, inflammatory diseases and osteoporosis. | 07-15-2010 |
20110034531 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA - The invention relates to the use of an HDAC inhibitor, more specifically or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of melanoma; the use of an HDAC inhibitor or a pharmaceutically acceptable salt thereof in the treatment of melanoma; a method of treating warm-blooded animals including mammals, especially humans, suffering from melanoma by administering to a said animal in need of such treatment a dose effective against said disease of an HDAC inhibitor or a pharmaceutically acceptable salt thereof. | 02-10-2011 |
20110118309 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF HODGKIN'S DISEASE - The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I): | 05-19-2011 |
20110124701 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF LYMPHOMAS - The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula (I): | 05-26-2011 |
20110288144 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF MELANOMA - The invention relates to the use of an HDAC inhibitor, more specifically or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of melanoma; the use of an HDAC inhibitor or a pharmaceutically acceptable salt thereof in the treatment of melanoma; a method of treating warm-blooded animals including mammals, especially humans, suffering from melanoma by administering to a said animal in need of such treatment a dose effective against said disease of an HDAC inhibitor or a pharmaceutically acceptable salt thereof. | 11-24-2011 |
20120029047 | USE OF HDAC INHIBITORS FOR THE TREATMENT OF BONE DESTRUCTION - The present invention relates to the use of HDAC inhibitors for the treatment of bone destruction caused by cancer, inflammatory diseases and osteoporosis. | 02-02-2012 |
20130029927 | COMBINATION OF LBH589 WITH OTHER THERAPEUTIC AGENTS FOR TREATING CANCER - The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination. | 01-31-2013 |
20130171141 | COMBINATION OF HDAC INHIBITORS WITH THROMBOCYTOPENIA DRUGS - The invention relates to a combination which comprises:
| 07-04-2013 |